Person: YURTSEVER, İSMAİL
Loading...
Status
Organizational Units
8 results
Search Results
Now showing 1 - 8 of 8
Publication Metadata only Relationship between KRAS mutation and diffusion weighted imaging in colorectal liver metastases; Preliminary study.(2020-02-25T00:00:00Z) Türk, HM; Gültekin, MEHMET ALİ; Uysal, Ö; Beşiroğlu, M; Yilmaz, TF; Yurtsever, I; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; TOPRAK, HÜSEYİN; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; SHARIFOV, RASUL; UYSAL, ÖMERPurpose: We aimed to investigate whether there are any differences in apparent diffusion coefficient (ADC) values obtained from colorectal liver metastases (CRLM) according to Kirsten rat sarcoma (KRAS) gene mutation status.Publication Metadata only Meme kanseri beyin metastazlarının moleküler subgruplarının difüzyon tensor görüntüleme ile değerlendirilmesi(2019-04-27T00:00:00Z) Yurtsever, İsmail; Gültekin, Mehmet Ali; Yılmaz, Temel Fatih; Türk, Hacı Mehmet; Alkan, Alpay; YURTSEVER, İSMAİL; GÜLTEKİN, MEHMET ALİ; YILMAZ, TEMEL FATİH; TÜRK, HACI MEHMET; ALKAN, ALPAYPublication Metadata only Akciğer kanserli olgularda intrakranial metastazlarının primer hücre tipinin belirlenmesinde DTG’nin etkinliği(2018-11-10T00:00:00Z) Bilgin, Mehmet; Yurtsever, İsmail; Türk, Hacı Mehmet; Alkan, Alpay; BİLGİN, MEHMET; YURTSEVER, İSMAİL; TÜRK, HACI MEHMET; ALKAN, ALPAYPublication Metadata only The Utility and Efficiency of Diffusion Tensor Imaging Values to Determine Epidermal Growth Factor Receptor Gene Mutation Status in Brain Metastasis from Lung Adenocarcinoma; A Preliminary Study(2021-02-01T00:00:00Z) Gültekin, Mehmet Ali; Alkan, Alpay; Yılmaz, Temel Fatih; Yurtsever, İsmail; Atasoy, Bahar; Aliyev, Altay; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; YURTSEVER, İSMAİL; YILMAZ, TEMEL FATİH; ALKAN, ALPAYPublication Metadata only A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer(2021-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, Mesut; TÜRK, HACI MEHMET; TOPÇU, ATAKAN; YASİN, AYŞE İREM; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, MESUT; TÜRK, HACI MEHMETIntroduction Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.Publication Metadata only Relationship with programmed cell death ligand 1 (PD-L1) and DTI features in brain metastases of non-small cell lung cancer; Preliminary study.(2021-02-17T00:00:00Z) Yurtsever, İsmail; Yilmaz, Temel Fatih; Turk, Hacı Mehmet; Gultekin, Mehmet Ali; Besiroglu, Mehmet; Cesme, DİLEK HACER; Shbair, Abdallah T M; Alkan, ALPAY; YILMAZ, TEMEL FATİH; YURTSEVER, İSMAİL; TÜRK, HACI MEHMET; GÜLTEKİN, MEHMET ALİ; ÇEŞME, DİLEK HACER; ALKAN, ALPAYPublication Metadata only Diffusion Tensor Imaging of Brain Metastases in Patients with Breast Cancer According to Molecular Subtypes.(2020-06-21T00:00:00Z) Turk, HM; Sari, L; Yurtsever, I; Yabaci, A; Peker, AA; Alkan, ALPAY; YURTSEVER, İSMAİL; GÜLTEKİN, MEHMET ALİ; TOPRAK, HÜSEYİN; TÜRK, HACI MEHMET; YABACI TAK, AYŞEGÜL; ALKAN, ALPAYPublication Metadata only Apparent Diffusion Coefficient Values for Neuroendocrine Liver Metastases.(2020-11-07T00:00:00Z) Gultekin, MA; Cesme, DH; Yurtsever, I; Turk, HM; Seker, M; Besiroglu, M; Alkan, ALPAY; GÜLTEKİN, MEHMET ALİ; TÜRK, HACI MEHMET; YURTSEVER, İSMAİL; ÇEŞME, DİLEK HACER; ALKAN, ALPAY